DongKook Pharmaceutical (086450) Fundamentals 2026 — P/E 10.9x, Revenue Analysis | SniperIQ
DongKook Pharmaceutical (086450) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩821.0B, trading at ₩18200.00 on the KOE. This SniperIQ fundamentals page covers DongKook Pharmaceutical's valuation (P/E 10.9x, P/B 1.2x), profitability (net margin 7.8%), revenue (₩926.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is DongKook Pharmaceutical's market cap?
DongKook Pharmaceutical (086450) has a market capitalization of approximately ₩821.0B, trading at ₩18200.00 on the KOE. Market cap moves with the live share price.
What is DongKook Pharmaceutical's P/E ratio?
DongKook Pharmaceutical's trailing twelve-month P/E ratio is 10.9x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is DongKook Pharmaceutical?
DongKook Pharmaceutical runs a net profit margin of 7.8%, a gross margin of 54.5%, and an operating margin of 10.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does DongKook Pharmaceutical generate?
DongKook Pharmaceutical reported revenue of ₩926.9B for fiscal year 2025, with net income of ₩66.0B and earnings per share (EPS) of 1487. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does DongKook Pharmaceutical pay a dividend?
DongKook Pharmaceutical offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is DongKook Pharmaceutical financially healthy?
DongKook Pharmaceutical carries a debt-to-equity ratio of 0.10x and a current ratio of 2.06x, with a market beta of -0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is DongKook Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DongKook Pharmaceutical (086450) the key facts are: market cap ₩821.0B, P/E 10.9x, revenue ₩926.9B, 52-week range 16260-31250. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track DongKook Pharmaceutical's full fundamentals live
Get DongKook Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.